We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Artios

News List

Researchers identify new drug class with potential in BRCA-mutated tumours pharmatimes
June 21, 2021
Researchers from the The Institute of Cancer Research, London and Artios have identified a new class of drugs – POLQ inhibitors – which could have potential for patients with BRCA-mutated tumours.
Artios, Novartis form cancer therapies collaboration pharmatimes
April 08, 2021
Artios Pharma and Novartis have formed a global research collaboration to discover and validate next generation DNA damage response (DDR) targets to enhance the Swiss drugmaker's radioligand therapies (RLT).
Artios bags $84M to trial next-generation DNA damage response drugs fiercebiotech
August 13, 2018
Artios Pharma has raised $84 million (£65 million) to take DNA damage response (DDR) programs to clinical proof of concept. The series B round sees more big-name investors give cash to researchers whose earlier work on PARP inhibitor Lynparza put DDR on t